modest still track growth acceler reiter ow
invest summari reiter overweight rate pt
follow modest beat post sale vs
factset consensu deliv better expect constant currenc growth
expect adjust ep penni higher
consensu manag re-affirmed guidanc still see
achiev continu execut short-term object
modest beat overli impress think combin posit
manag commentari call enough maintain investor confid
turnaround remain track four key knee product
approv limit launch growth inflect point
compani work back market growth
 modest top bottom line beat revenu organ
beat factset consensu organ growth deceler sequenti
quarter although sell day headwind
apac emea continu perform well grow
respect ep beat penni better expect gm driven
fx hedg gain lower interest expens off-set higher sg spend
guidanc still look achiev reiter full-year
guidanc state confid capac suppli new product
deliv financi commit believ full launch new
knee product partial cementless revis rosa tka drive top-
line acceler premium price potenti market share captur
lower revenu estim rais
ep estim penni left revenu ep
prepar go offens continu execut short-
term goal suppli recoveri shift improv suppli effici
remedi plan warsaw north campu track complet
year end see busi stabil get back consist
growth posit compani execut year plan
includ acceler revenu growth margin expans increas
 valuat pt base price-to-earnings ep estim
disclosur section may found page
sourc compani document factset cantor fitzgerald estim
exhibit comparison cantor estim
compani document factset cantor fitzgerald estim
inc million except per dilut inc million except per share current priorcurr priorp growth gener adminstr incom expens tax provis dilut share april
zbh oper issu leadership uncertainti warrant discount peer
 said think zbh valuat could quickli rebound move toward histor
averag post coupl strong quarter rebuild investor confid price target
base price-to-earnings multipl ep estim
may abl recaptur share lost meaning amount hip knee share
last two year histor share shift given year ten basi
point may abl recaptur share quickli lost
larg ou exposur subject addit risk deriv net sale
outsid zbh larg intern oper expos number addit risk
includ fx risk polit econom instabl unexpect chang foreign regulatori
requir foreign medic reimburs polici
cut effort healthcar purchas organ may materi advers effect
zbh financi result mani zbh custom form group purchas organ
effort contain cost failur respond cost-contain effort group purchas
organ could materi advers effect sale margin
fda could take addit action fda conduct recent inspect found
observ said on-track remedi plan address old new
observ anticip fda could potenti issu warn letter take
action could neg affect zbh oper
million except per share data
cost good sold
sell gener adminstr
incom incom tax
sell gener adminstr
amort intang
sell gener adminstr
compani document cantor fitzgerald research
zimmer biomet headquart warsaw indiana found becam public compani august spun
bristol-my squibb june zimmer acquir biomet deal creat current zimmer biomet pure-
play orthoped compani knee revenu hip revenu make total compani sport medicin
extrem trauma spine dental sale
